1. Home
  2. KNF vs IMVT Comparison

KNF vs IMVT Comparison

Compare KNF & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knife Riv Holding Co.

KNF

Knife Riv Holding Co.

HOLD

Current Price

$77.93

Market Cap

5.0B

Sector

N/A

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$24.74

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNF
IMVT
Founded
1917
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.4B
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
KNF
IMVT
Price
$77.93
$24.74
Analyst Decision
Buy
Buy
Analyst Count
8
9
Target Price
$97.38
$30.78
AVG Volume (30 Days)
510.8K
920.5K
Earning Date
05-20-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.76
N/A
Revenue
$3,146,012,000.00
N/A
Revenue This Year
$9.15
N/A
Revenue Next Year
$5.53
N/A
P/E Ratio
$28.32
N/A
Revenue Growth
8.52
N/A
52 Week Low
$58.72
$12.72
52 Week High
$101.02
$29.25

Technical Indicators

Market Signals
Indicator
KNF
IMVT
Relative Strength Index (RSI) 40.10 36.35
Support Level $76.66 $24.63
Resistance Level $79.11 $27.71
Average True Range (ATR) 3.25 1.14
MACD -1.56 -0.29
Stochastic Oscillator 5.69 3.44

Price Performance

Historical Comparison
KNF
IMVT

About KNF Knife Riv Holding Co.

Knife River Holding Co is an aggregates-led construction materials and contracting services provider. The segments of the company include West, Mountain, Central, and Energy Services. Each geographic segment offers a vertically integrated suite of products and services, including aggregates, ready-mix concrete, asphalt, and contracting services, while the Energy Services segment, which has locations throughout the company's geographic footprint, produces and supplies liquid asphalt and related services, for use in asphalt road construction, and is a supplier to some of the other segments.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: